Back to Search
Start Over
Experience in Course of Anti-IgE Therapy of Bronchial Asthma in Children
- Source :
- Rossijskij Vestnik Perinatologii i Pediatrii, Vol 65, Iss 6, Pp 116-121 (2021)
- Publication Year :
- 2021
- Publisher :
- The National Academy of Pediatric Science and Innovation, 2021.
-
Abstract
- The results of the clinical approbation of Patient-specific therapy of bronchial asthma in children using the course method of applicationof the monoclonal antibodies (anti-IgE-therapy) by the Ministry of Health are summarized in order to assess the effect of this typeof treatment on the disease exacerbation rate, including those associated with the seasonal acute respiratory infections. The conclusion was made regarding the high clinical efficiency in relation to all parameters studied and safety of this type of the treatment. Itwas determined that the monitoring of the level of specific IgE receptors on basophils using the cytoflowmetry method, which is concomitant to anti-IgE therapy, makes it possible to predict the efficiency and individual duration of anti-IgE therapy for uncontrolledatopic bronchial asthma in children.
- Subjects :
- 0301 basic medicine
genetic structures
medicine.drug_class
clinical efficiency
cytoflowmetry
ige receptors on basophils
Immunoglobulin E
Monoclonal antibody
Pediatrics
RJ1-570
respiratory infections
03 medical and health sciences
0302 clinical medicine
children
medicine
Disease Exacerbation
Asthma
biology
business.industry
exacerbation rate
omalizumab course treatment
medicine.disease
030104 developmental biology
030228 respiratory system
Concomitant
Pediatrics, Perinatology and Child Health
Immunology
biology.protein
Christian ministry
bronchial asthma
business
Subjects
Details
- ISSN :
- 25002228 and 10274065
- Volume :
- 65
- Database :
- OpenAIRE
- Journal :
- Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)
- Accession number :
- edsair.doi.dedup.....3f38d464cb21366fc9f5f8c4d1f5ebc6
- Full Text :
- https://doi.org/10.21508/1027-4065-2020-65-6-116-121